CNTX

Context Therapeutics Stock Analysis

AI Rating

Good
  • Quality2/10
  • Growth 7/10
  • Momentum 9/10
Context Therapeutics sales and earnings growth
CNTX Growth
Good
  • Revenue Y/Y 0.00%
  • EPS Y/Y 73.63%
  • FCF Y/Y -32.57%
Context Therapeutics gross and profit margin trends
CNTX Profitability
Low
  • Gross margin 0.00%
  • EPS margin 0.00%
  • ROIC 8256.50%
Context Therapeutics net debt vs free cash flow
CNTX Risk
Great
  • Debt / Equity 0.0
  • Debt / FCF 0.0
  • Interest coverage NA

Context Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗